Showing 2401-2410 of 4063 results for "".
- GenSight Biologics Reports Positive Additional Data From REVERSE Phase 3 Clinical Trial of GS010 for Treatment of LHONhttps://modernod.com/news/gensight-biologics-reports-positive-additional-data-from-reverse-phase-3-clinical-trial-of-gs010-for-treatment-of-leber-hereditary-optic-neuropathy-lhon/2480100/GenSight Biologics reported additional results from the REVERSE phase 3 clinical trial evaluating the safety and efficacy of a single intravitreal injection of GS010 (rAAV2/2-ND4)in patients with Leber Hereditary Optic Neuropathy (LHON). The study involved 37 patients with visual loss du
- Lighthouse Guild Offers eLearning Course on Low Vision Assessment for Occupational Therapyhttps://modernod.com/news/lighthouse-guild-offers-elearning-course-on-low-vision-assessment-for-occupational-therapy/2480221/Lighthouse Guild, in partnership with the American Occupational Therapy Association (AOTA), is offering a 2-hour online program designed for occupational therapists in all settings. The course titled “Low Vision Assessment for Occupational Therapy” demonstrates the basic strategies and tools for
- Cure Blindness Project Releases 2025 Impact Report Highlighting Global Reach and Restored Visionhttps://modernod.com/news/cure-blindness-project-releases-2025-impact-report-highlighting-global-reach-and-restored-vision/2487240/Cure Blindness Project has released its 2025 Impact Report, detailing significant progress in expanding access to eye care and preventing avoidable blindness worldwide. The re
- CooperVision to Spotlight New Clinical Research at BCLA Asia 2026https://modernod.com/news/coopervision-to-spotlight-new-clinical-research-at-bcla-asia-2026/2487226/Key Takeaways New CooperVision research at BCLA Asia 2026 highlights practical strategies to improve myopia management adoption, including stage-based parent education approaches d
- The Vision Council Opens Registration for 2026 Lab Leadership Forum in Las Vegashttps://modernod.com/news/the-vision-council-opens-registration-for-2026-lab-leadership-forum-in-las-vegas/2487132/The Vision Council has opened registration for the 2026 Lab Leadership Forum, the organization’s flagship event for optical lab professionals, scheduled for Sept. 16-18, 2026, at the M Resort Spa Casino in Las Vegas. The annual
- Lumenis Expands Peer-to-Peer Education With 2026 Accelerate Series for Eye Care Professionalshttps://modernod.com/news/lumenis-expands-peer-to-peer-education-with-2026-accelerate-series-for-eye-care-professionals/2487031/Lumenis announced the launch of its 2026 Accelerate education series, a nationwide peer-to-peer learning initiative designed to help eye care professionals expand procedural services, strengthen clinical confidence, and integrate advanced therapeutic technologies in
- AOA Honors Leaders in Optometry With 2025 Annual Awardshttps://modernod.com/news/aoa-honors-leaders-in-optometry-with-2025-annual-awards/2487030/The American Optometric Association (AOA), the American Optometric Student Association (AOSA) and The AOA Foundation have announced the recipients of the organizations’ 2025
- Johnson & Johnson Showcases New Vision Research at ARVO 2026https://modernod.com/news/johnson-johnson-showcases-new-vision-research-at-arvo-2026/2486943/Johnson & Johnson Vision is presenting a broad range of new clinical and preclinical data at the 2026 Association for Research in Vision and Ophthalmology (ARVO) annual meeting in Denver, highlighting advancements across IOLs, contact lenses, and myopia manageme
- Revenio Group to Acquire Visionix in 290 Million Euro Dealhttps://modernod.com/news/revenio-group-to-acquire-visionix-in-290-million-euro-deal/2486649/Revenio Group has signed an agreement to acquire the entire share capital of France-based LT International SAS, the parent company of the Visionix International group, in a transaction valued at €290 million ($342 million). T
- FDA Issues Third Complete Response Letter to Aldeyra Therapeutics for Dry Eye Drug Reproxalaphttps://modernod.com/news/fda-issues-third-complete-response-letter-to-aldeyra-therapeutics-for-dry-eye-drug-reproxalap/2486097/In another setback for Aldeyra Therapeutics, the FDA issued a third Complete Response Letter (CRL) regarding its new drug application (NDA) for investigational dry eye treatment reproxalap. In the letter, the FDA stated that th